Design, synthesis, and biological evaluation of 6-methoxy-2-arylquinolines as potential P-glycoprotein inhibitors

Document Type: Original Article

Authors

1 Biotechnology Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran

2 Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Objective(s): In the present study,a new series of 6-methoxy-2-arylquinoline analogues was designed and synthesized as P-glycoprotein (P-gp) inhibitors using quinine and flavones as the lead compounds.
Materials and Methods: The cytotoxic activity of the synthesized compounds was evaluated against two human cancer cell lines including EPG85-257RDB, multidrug-resistant gastric carcinoma cells (P-gp-positive gastric carcinoma cell line), and EPG85-257P, drug-sensitive gastric carcinoma cells. Compounds showing low to moderate toxicity in the MTT test were selected to investigate their P-gp inhibition activity. Moreover, trying to explain the results of biological experiments, docking studies of the selected compounds into the homology-modeled human P-gp, were carried out. The physicochemical and ADME properties of the compounds as drug candidate were also predicted.
Results: Most of our compounds exhibited negligible or much lower cytotoxic effect in both cancer cells. Among the series, 5a and 5b, alcoholic quinoline derivatives were found to inhibit the efflux of rhodamine 123 at the concentration of 10 μM significantly.
Conclusion: Among the tested quinolines, 5a and 5b showed the most potent P-gp inhibitory activity in the series and were 1.3-fold and 2.1-fold stronger than verapamil, respectively. SAR data revealed that hydroxyl methyl in position 4 of quinolines has a key role in P-gp efflux inhibition of our compounds. ADME studies suggested that all of the compounds included in this study may have a good human intestinal absorption.

Keywords

Main Subjects


1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29.

2. Cozzi P. The discovery of a new potential anticancer drug: a case history. Farmaco  2003; 58: 213-220.

3. Liang XJ, Chen C, Zhao Y, Wang PC. Circumventing tumor resistance to chemotherapy by nanotechnology. Methods Mol Biol  2010; 596: 467-488.

4. Capparelli E, Zinzi L, Cantore M, Contino M, Perrone MG, Luurtsema G, et al. SAR studies on tetrahydroisoquinoline derivatives: the role of flexibility and bioisosterism to raise potency and selectivity toward P-glycoprotein.  J  Med Chem 2014; 57: 9983-9994.

5. Wang Z, Wong IL, Li FX, Yang C, Liu Z, Jiang T, et al. Optimization of permethyl ningalin B analogs as P-glycoprotein inhibitors. Bioorg Med Chem 2015; 23: 5566-5573.

6. Chen CY, Liu NY, Lin HC, Lee CY, Hung CC, Chang CS. Synthesis and bioevaluation of novel benzodipyranone derivatives as P-glycoprotein inhibitors for multidrug resistance reversal agents. Eur J  Med Chem 2016; 118: 219-229.

7. Kuriakose J, Hrycyna CA, Chmielewski J. Click chemistry-derived bivalent quinine inhibitors of P-glycoprotein-mediated cellular efflux. Bioorg Med Chem lett 2012; 22: 4410-4412.

8. Lopes-Rodrigues V, Oliveira A, Correia-da-Silva M, Pinto M, Lima RT, Sousa E, et al. A novel curcumin derivative which inhibits P-glycoprotein, arrests cell cycle and induces apoptosis in multidrug resistance cells. Bioorg Med Chem 2017; 25: 581-596.

9. Zeslawska E, Kincses A, Spengler G, Nitek W, Wyrzuc K, Kiec-Kononowicz K, et al. The 5-aromatic hydantoin-3-acetate derivatives as inhibitors of the tumour multidrug resistance efflux pump P-glycoprotein (ABCB1): Synthesis, crystallographic and biological studies. Bioorg Med Chem 2016; 24: 2815-2822.

10. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Research 1981; 41: 1967-1972.

11. Tsuruo T, Iida H, Kitatani Y, Yokota K, Tsukagoshi S, Sakurai Y. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells. Cancer Research 1984; 44: 4303-4307.

12. Shiraishi N, Akiyama S, Kobayashi M, Kuwano M. Lysosomotropic agents reverse multiple drug resistance in human cancer cells. Cancer Lett 1986; 30: 251-259.

13. Riffkin CD, Chung R, Wall DM, Zalcberg JR, Cowman AF, Foley M, et al. Modulation of the function of human MDR1 P-glycoprotein by the antimalarial drug mefloquine. Biochem Pharmacol 1996; 52: 1545-1552.

14. Avendano C, Menendez JC. Inhibitors of multidrug resistance to antitumor agents (MDR). Curr Med Chem 2002; 9: 159-193.

15. Warner E, Hedley D, Andrulis I, Myers R, Trudeau M, Warr D, et al. Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen. Clin Cancer Res 1998; 4: 1451-1457.

16. Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, Booser D, et al. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 2005; 104: 682-691.

17. Salar Bashi D, Fazly Bazzaz BS, Sahebkar A, Karimkhani MM, Ahmadi A. Investigation of optimal extraction, antioxidant, and antimicrobial activities of Achillea biebersteinii and A. wilhelmsii. Pharm Biol 2012; 50: 1168-1176.

18. Bansal T, Jaggi M, Khar RK, Talegaonkar S. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci 2009; 12: 46-78.

19. Wu Y, Pan M, Dai Y, Liu B, Cui J, Shi W, et al. Design, synthesis and biological evaluation of LBM-A5 derivatives as potent P-glycoprotein-mediated multidrug resistance inhibitors. Bioorg Med Chem 2016; 24: 2287-2297.

20. Malayeri SO, Abnous K, Arab A, Akaberi M, Mehri S, Zarghi A, et al. Design, synthesis and biological evaluation of 7-(aryl)-2,3-dihydro-[1,4]dioxino[2,3-g]quinoline derivatives as potential Hsp90 inhibitors and anticancer agents. Bioorg Med Chem 2017; 25: 1294-1302.

21. Shobeiri N, Rashedi M, Mosaffa F, Zarghi A, Ghandadi M, Ghasemi A, et al. Synthesis and biological evaluation of quinoline analogues of flavones as potential anticancer agents and tubulin polymerization inhibitors. Eur J  Med Chem. 2016; 114: 14-23.

22. Wu Y, Chen Z, Liu Y, Yu L, Zhou L, Yang S, et al. Quinoline-4-methyl esters as human nonpancreatic secretory phospholipase A(2) inhibitors. Bioorg Med Chem 2011; 19: 3361-3366.

23. Ghodsi R, Azizi E, Grazia Ferlin M, Pezzi V, Zarghi A. Design, synthesis and biological evaluation of 4-(imidazolylmethyl)-2-aryl-quinoline derivatives as aromatase inhibitors and anti-breast cancer agents. Lett Drug Des  Discov 2016; 13: 89-97.

24. Baumert C, Günthel M, Krawczyk S, Hemmer M, Wersig T, Langner A, et al. Development of small-molecule P-gp inhibitors of the N-benzyl 1,4-dihydropyridine type: Novel aspects in SAR and bioanalytical evaluation of multidrug resistance (MDR) reversal properties. Bioorg Med Chem 2013; 21: 166-177.

25. Li XQ, Wang L, Lei Y, Hu T, Zhang FL, Cho CH, et al. Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives. Eur J  Med Chem 2015; 101: 560-572.

26. Hosseinzadeh H, Mazaheri F, Ghodsi R. Pharmacological effects of a synthetic quinoline, a hybrid of tomoxiprole and naproxen, against acute pain and inflammation in mice: a behavioral and docking study. Iran J Basic Med Sci 2017; 20: 446-450.

27. Abdizadeh T, Kalani MR, Abnous K, Tayarani-Najaran Z, Khashyarmanesh BZ, Abdizadeh R, et al. Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents. Eur J  Med Chem 2017; 132: 42-62.